Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65

Abstract Introduction Respiratory syncytial virus (RSV) and influenza pose major disease burdens in older adults due to an aging immune system and comorbidities; seasonal overlap exists between these infections. In 2023, the RSV prefusion protein F3 older adult (RSVPreF3 OA) vaccine was first approv...

Full description

Bibliographic Details
Main Authors: Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-06-01
Series:Infectious Diseases and Therapy
Subjects:
High-dose, quadrivalent influenza vaccine (FLU-QIV-HD)
Immunogenicity
Older adults
Randomized controlled trial
Reactogenicity
Respiratory syncytial virus (RSV)
Online Access:https://doi.org/10.1007/s40121-024-00985-4

Internet

https://doi.org/10.1007/s40121-024-00985-4

Similar Items